TY - JOUR
T1 - PCA3 score of 20 could improve prostate cancer detection: Results
obtained on 734 Italian individuals
AU - Capoluongo, Ettore Domenico
AU - Zambon, Carlo Federico
AU - Basso, Daniela
AU - Boccia, Stefania
AU - Rocchetti, Sandro
AU - Leoncini, Emanuele
AU - Palumbo, Sara
AU - Padoan, Andrea
AU - Albino, Giuseppe
AU - Todaro, Angelo
AU - Prayer-Galetti, Tommaso
AU - Zattoni, Filiberto
AU - Zuppi, Cecilia
AU - Plebani, Mario
PY - 2014
Y1 - 2014
N2 - Background: The role of PCa3 score in the diagnostics of prostate cancer
(PCa) is still under debate, mainly due to the lack of a univocal
cut-off useful alone or within nomograms proposed by Urologists. Aim of
present study is to compare different PCA3 score cut-off values (20, 25,
35 and 50) observed in 734 patients with suspected PCa who were
monitored for about three years with single or multiple biopsies.
Methods: 734 patients who underwent first prostate biopsy for suspected
PCa were enrolled. One month later the first biopsy result was obtained,
both negative and positive PCa patients were investigated by means of
PCA3 score, in order to establish risk of PCa presence on repeated
biopsies.
Results: PCA3 score was significantly higher (p < 0.001) in PCa patients
to the PCa negative ones, while tPSA did not significantly vary. The
best negative predictive value (NPV 97.5\%) and sensitivity (95.4\%)
result were obtained when a PCA3 score of 20 was used. At cut-off value
of 50, the 75\% of patients resulted as false positive.
Conclusions: PCA3 score of 20 could be safely introduced in the prostate
cancer screening diagnostic flow chart, since it provides important
information regarding the outcome of re-biopsy. (C) 2013 Elsevier B.V.
All rights reserved.
AB - Background: The role of PCa3 score in the diagnostics of prostate cancer
(PCa) is still under debate, mainly due to the lack of a univocal
cut-off useful alone or within nomograms proposed by Urologists. Aim of
present study is to compare different PCA3 score cut-off values (20, 25,
35 and 50) observed in 734 patients with suspected PCa who were
monitored for about three years with single or multiple biopsies.
Methods: 734 patients who underwent first prostate biopsy for suspected
PCa were enrolled. One month later the first biopsy result was obtained,
both negative and positive PCa patients were investigated by means of
PCA3 score, in order to establish risk of PCa presence on repeated
biopsies.
Results: PCA3 score was significantly higher (p < 0.001) in PCa patients
to the PCa negative ones, while tPSA did not significantly vary. The
best negative predictive value (NPV 97.5\%) and sensitivity (95.4\%)
result were obtained when a PCA3 score of 20 was used. At cut-off value
of 50, the 75\% of patients resulted as false positive.
Conclusions: PCA3 score of 20 could be safely introduced in the prostate
cancer screening diagnostic flow chart, since it provides important
information regarding the outcome of re-biopsy. (C) 2013 Elsevier B.V.
All rights reserved.
KW - PCA3 score
KW - Progensa
KW - PCA3 score
KW - Progensa
UR - http://hdl.handle.net/10807/57405
U2 - 10.1016/j.cca.2013.10.022
DO - 10.1016/j.cca.2013.10.022
M3 - Article
SN - 0009-8981
VL - 429
SP - 46
EP - 50
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
ER -